Cargando…

Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau

Objective: New diagnostic criteria for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) have been developed using biomarkers aiming to establish whether the clinical syndrome is likely due to underlying AD. We investigated the utility of magnetic resonance imaging (MRI) and cereb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dickerson, Bradford C., Wolk, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795312/ https://www.ncbi.nlm.nih.gov/pubmed/24130528 http://dx.doi.org/10.3389/fnagi.2013.00055

Ejemplares similares

Heterogeneity of Tau Deposition and Microvascular Involvement in MCI and AD
por: Bryant, Annie G., et al.
Publicado: (2021)

Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid
por: Luis, Cheryl A., et al.
Publicado: (2011)

Head injury is associated with tau deposition on PET in MCI and AD patients
por: Risacher, Shannon L., et al.
Publicado: (2021)

Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
por: Ferrari-Souza, João Pedro, et al.
Publicado: (2022)

Brain signatures based on structural MRI: Classification for MCI, PMCI, and AD
por: Gonuguntla, Venkateswarlu, et al.
Publicado: (2022)

Simultaneous FDG-PET/MRI detects hippocampal subfield metabolic differences in AD/MCI
por: Carlson, Mackenzie L., et al.
Publicado: (2020)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Evaluation of tau deposition using (18)F-PI-2620 PET in MCI and early AD subjects—a MissionAD tau sub-study
por: Bullich, Santiago, et al.
Publicado: (2022)

Assessment of PET & ASL metabolism in the hippocampal subfields of MCI and AD using simultaneous PET-MR
por: Goubran, Maged, et al.
Publicado: (2015)

Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers
por: Shen, Li, et al.
Publicado: (2013)

The paradox of opposite directions of gene expressions in MCI and AD suggests possible therapy to prevent progression of MCI to AD
por: Fessel, Jeffrey
Publicado: (2020)

Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
por: Lee, Jinny Claire, et al.
Publicado: (2019)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease
por: Park, Sun Ah, et al.
Publicado: (2020)

Decreasing Social Support Associated With Risk of MCI and Dementia Is Partially Mediated by Hippocampal Volume
por: Gruenewald, Tara, et al.
Publicado: (2020)

Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals
por: Chipi, Elena, et al.
Publicado: (2019)

Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers()()
por: Da, Xiao, et al.
Publicado: (2013)

An MRI-Derived Definition of MCI-to-AD Conversion for Long-Term, Automatic Prognosis of MCI Patients
por: Aksu, Yaman, et al.
Publicado: (2011)

Preoperative cerebrospinal fluid β-Amyloid/Tau ratio and postoperative delirium
por: Xie, Zhongcong, et al.
Publicado: (2014)

Quantitative Assessment of Hippocampal Tau Pathology in AD and PART
por: Zhang, Lei, et al.
Publicado: (2020)

Transcriptional Signatures of Tau and Amyloid Neuropathology
por: Castanho, Isabel, et al.
Publicado: (2020)

CSF tau and β-amyloid as biomarkers for mild cognitive impairment
por: Hampel, Harald, et al.
Publicado: (2004)

Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau
por: Lafirdeen, Aysha S. Mohamed, et al.
Publicado: (2019)

A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease
por: Turk, Katherine W., et al.
Publicado: (2022)

Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid
por: Voyle, Nicola, et al.
Publicado: (2016)

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
por: Ashton, N. J., et al.
Publicado: (2021)

PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers
por: Koychev, Ivan, et al.
Publicado: (2017)

Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
por: Erickson, Pontus, et al.
Publicado: (2023)

Both Amyloid-β Peptide and Tau Protein Are Affected by an Anti-Amyloid-β Antibody Fragment in Elderly 3xTg-AD Mice
por: Roda, Alejandro R., et al.
Publicado: (2020)

AD-NET: Age-adjust neural network for improved MCI to AD conversion prediction
por: Gao, Fei, et al.
Publicado: (2020)

Distinct amyloid and tau PET signatures are associated with diverging clinical and imaging trajectories in patients with amnestic syndrome of the hippocampal type
por: Lagarde, Julien, et al.
Publicado: (2021)

CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume
por: Düzel, Emrah, et al.
Publicado: (2018)

In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion
por: Hessen, Erik, et al.
Publicado: (2019)

Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment
por: Garrett, Stephanie L., et al.
Publicado: (2019)

Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals
por: d'Oleire Uquillas, Federico, et al.
Publicado: (2017)

Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging
por: Ottoy, Julie, et al.
Publicado: (2019)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD)
por: Bauckneht, Matteo, et al.
Publicado: (2018)

Sleep Disturbances in MCI and AD: Neuroinflammation as a Possible Mediating Pathway
por: Pak, Victoria M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_efv3h5u9fkkft0s2pfhe56set8